AU755743B2 - Porcine nuclear transfer - Google Patents
Porcine nuclear transfer Download PDFInfo
- Publication number
- AU755743B2 AU755743B2 AU29135/99A AU2913599A AU755743B2 AU 755743 B2 AU755743 B2 AU 755743B2 AU 29135/99 A AU29135/99 A AU 29135/99A AU 2913599 A AU2913599 A AU 2913599A AU 755743 B2 AU755743 B2 AU 755743B2
- Authority
- AU
- Australia
- Prior art keywords
- porcine
- cell
- cells
- karyoplast
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000012546 transfer Methods 0.000 title description 24
- 210000004027 cell Anatomy 0.000 claims description 76
- 210000000287 oocyte Anatomy 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 46
- 210000002308 embryonic cell Anatomy 0.000 claims description 41
- 210000002257 embryonic structure Anatomy 0.000 claims description 37
- 230000008569 process Effects 0.000 claims description 33
- 241000282887 Suidae Species 0.000 claims description 26
- 238000011161 development Methods 0.000 claims description 23
- 230000031864 metaphase Effects 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 230000035935 pregnancy Effects 0.000 claims description 16
- 230000001360 synchronised effect Effects 0.000 claims description 16
- 230000032823 cell division Effects 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 13
- 231100000782 microtubule inhibitor Toxicity 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 229940122255 Microtubule inhibitor Drugs 0.000 claims description 10
- 229940122029 DNA synthesis inhibitor Drugs 0.000 claims description 9
- 210000001161 mammalian embryo Anatomy 0.000 claims description 9
- 210000004291 uterus Anatomy 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 235000003642 hunger Nutrition 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 230000037351 starvation Effects 0.000 claims description 5
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 claims description 4
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 claims description 4
- 230000001052 transient effect Effects 0.000 claims description 4
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229940126074 CDK kinase inhibitor Drugs 0.000 claims 1
- 230000018109 developmental process Effects 0.000 description 19
- 210000004940 nucleus Anatomy 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000004927 fusion Effects 0.000 description 12
- 210000002459 blastocyst Anatomy 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 230000010190 G1 phase Effects 0.000 description 8
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 8
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 8
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 8
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 8
- 229950006344 nocodazole Drugs 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 210000000472 morula Anatomy 0.000 description 7
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 6
- 229960004409 cloprostenol Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000018199 S phase Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 239000012909 foetal bovine serum Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000003101 oviduct Anatomy 0.000 description 5
- 230000016087 ovulation Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 229960005069 calcium Drugs 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000004508 polar body Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000255969 Pieris brassicae Species 0.000 description 3
- 210000001109 blastomere Anatomy 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000007159 enucleation Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000036878 aneuploidy Diseases 0.000 description 2
- 231100001075 aneuploidy Toxicity 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940034629 chorulon Drugs 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 229940032383 estrumate Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical class CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IFEJLMHZNQJGQU-KXXGZHCCSA-M sodium;(z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(Cl)=C1 IFEJLMHZNQJGQU-KXXGZHCCSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- YGKUXRWMCOUTAL-LGUVXVKNSA-N 70852-29-8 Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)[C@@H]1[C@@H]([C@]2(O[C@H]22)C)C)C(=O)[C@@]11[C@H]2\C=C\C[C@H](C)CC(=O)CCC1=O YGKUXRWMCOUTAL-LGUVXVKNSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- LXQIGOPEYPYPQE-VLYVGLJQSA-N C[C@@H]1CCC[C@@H](O)CCC(=O)O[C@]23[C@@H](\C=C\C1)[C@H](O)C(=C(C)[C@H]2[C@H](Cc4ccccc4)NC3=O)C Chemical compound C[C@@H]1CCC[C@@H](O)CCC(=O)O[C@]23[C@@H](\C=C\C1)[C@H](O)C(=C(C)[C@H]2[C@H](Cc4ccccc4)NC3=O)C LXQIGOPEYPYPQE-VLYVGLJQSA-N 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 229940119336 Microtubule stabilizer Drugs 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000029803 blastocyst development Effects 0.000 description 1
- NGOLMNWQNHWEKU-DEOSSOPVSA-N butyrolactone I Chemical compound C([C@@]1(C(=O)OC)C(=C(O)C(=O)O1)C=1C=CC(O)=CC=1)C1=CC=C(O)C(CC=C(C)C)=C1 NGOLMNWQNHWEKU-DEOSSOPVSA-N 0.000 description 1
- FQYAPAZNUPTQLD-DEOSSOPVSA-N butyrolactone I Natural products COC1=C(c2ccc(O)cc2)[C@](Cc3ccc(O)c(CC=C(C)C)c3)(OC1=O)C(=O)O FQYAPAZNUPTQLD-DEOSSOPVSA-N 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
WO 99/46982 PCTIAU99/00165 -1- PORCINE NUCLEAR TRANSFER This invention relates to porcine nuclear transfer processes for the production of nuclear transferred porcine embryonic cells, processes for the clonal generation of pigs, production of transgenic and genetically modified pigs, and pigs so produced.
The reconstruction of animal embryos by the transfer of a nucleus from a donor cell to either an enucleated oocyte or one cell zygote allows in theory the cloning of animals, that is, the production of genetically identical individuals. Practice is quite different. Whilst claims have been made that certain procedures have application across a wide range of animals, experience has shown that techniques which may be effective in the cloning of animals of one species either do not work in other species, give rise to embryos with a very low efficiency such that cloning would be impractical, or give rise to embryos which fail to develop on introduction to a pregnancy competent uterine environment of a recipient animal. For example, see Prather et al, (1989), Biology of Reproduction 41, 414-448.
WO 97/07668 and WO 97/07669 describe a nuclear transfer method involving donor cells resulting from serum starvation. The techniques of these applications fail to develop embryos capable of developing in a pregnancy competent uterine environment in many animals, and as a consequence are generally ineffective for cloned embryo production, and development, such as in pigs.
The present invention provides processes for the high efficiency production of nuclear transferred porcine embryonic cells capable of high efficiency development in the pregnancy competent porcine uterine environment to give clonal infant animals.
In accordance with one aspect of the present invention there is provided a process for the production of nuclear transferred porcine embryonic cells which includes providing a porcine oocyte at the Metaphase II stage of development from which the chromosomal material is removed, transferring a porcine karyoplast at the GO or G1 (GO/GI) state into the oocyte to give a nuclear WO 99/46982 PCT/AU99/00165 -2transferred porcine embryonic cell, and optionally culturing the cell in vitro to allow one or more cell divisions to give a plurality of nuclear transferred embryonic cells.
The nuclear transferred porcine embryonic cell may be incubated to-form a 2 to 32 cell stage or mass, such as a 2 to 16 cell mass (that is, a plurality of cells), whereafter the cell mass may be synchronized at the GO/Gl state. A nuclear transferred karyoplast may be isolated from the cell mass, and transferred into a second enucleated oocyte at the Metaphase II stage of development or to an enucleated zygote or later stage embryo or embryonic cell to give a second nuclear transferred cell, which may be cultured in vitro, to allow one or more cell divisions to give a plurality of nuclear transferred porcine embryonic cells.
Karyoplasts may be synchronized at the G1/S boundary state by use of DNA synthesis inhibitor which arrests the karyoplast at the G1 phase and/or use of a microtubule inhibitor which following removal of the microtubule inhibitor results in synchronization of said karyoplast at the G1 phase, and/or use of means which do not involve serum starvation of cells. Karyoplasts may be synchronized at the GO phase by nutrient deprivation and/or chemical treatment.
In another aspect this invention relates to a process for the clonal generation or propagation of pigs which process includes providing a porcine oocyte at the Metaphase II stage of development from which the nucleus is removed, transferring a porcine donor karyoplast at the GO/G1 state into the oocyte to give an nuclear transferred cell, culturing the nuclear transferred cell in vitro to allow one or more cell divisions to give a plurality of nuclear transferred porcine embryonic cells, and thereafter transferring a plurality of porcine embryonic cells so produced into a pregnancy competent uterus of a female pig which at conclusion of the pregnancy term gives rise to one or more genetically identical off-spring.
A further aspect of this invention provides porcine embryonic cells and pigs when prepared according to the above process.
WO 99/46982 PCT/AU99/00165 -3- In another aspect of this invention there is provided a process as described above wherein the porcine karyoplast at the GO/G1 state is fused and activated in an enucleated porcine oocyte at the Metaphase II stage of development by application of one or multiple electrical pulses spaced in their order of application, or by other means of generating multiple transient increases in intracellular Ca levels.
In another aspect of this invention there is provided a cloned pig produced from a nuclear transferred porcine embryonic cell.
In another aspect of this invention there is provided use of cloned pigs in agriculture, for organ production, or oocyte and embryo production.
In one aspect of this invention there is provided a process for the production of nuclear transferred porcine embryonic cells. A porcine oocyte from which the nucleus is removed is fused with the nucleus of a porcine donor karyoplast. A karyoplast is a donor nucleus, or the nucleus of a donor cell surrounded by an envelope of cytoplasm, or donor cell. Porcine oocytes at the Metaphase
II
stage of development may be readily collected from the oviducts of ovulating pigs. Ovulation may be induced by administering gonadotrophins of various species origin to the pigs. In the practice of the present invention, oocytes can be collected on appearance of the first polar body or as soon as possible after ovulation. Alternatively immature oocytes collected from the ovaries of living or slaughtered pigs may be matured in vitro to the Metaphase II stage which is readily observable by microscopic evaluation.
The nucleus is removed from the porcine oocyte at the Metaphase II stage by standard techniques, such as aspiration of the first polar body and neighbouring cytoplasm containing the metaphase chromosomes (see for example Smith Wilmut (1989) Biol. Reprod. 40, 1027-1035), ultraviolet radiation (see for example Tsunoda et al (1988) J Reprod Fertil. 82, 173) or another enucleating influence.
WO 99/46982 PCT/AU99/00165 -4- The porcine karyoplast is transferred into the porcine oocyte at the Metaphase II state as mentioned above. The karyoplast which is at the G1 or GO state as will be described hereinafter, is transferred into the enucleated porcine oocyte by standard techniques in the field, such as cell fusion of the enucleated porcine oocyte and the karyoplasts (that is, as mentioned above, a cell or nucleus of a cell surrounded by an envelope of cytoplasm) or by direct injection of the karyoplast into the enucleated porcine oocyte. Established methods for inducing cell fusion include exposure of cells to fusion-promoting chemicals, such as polyethylene glycol (see, for example, Kanka et al, (1991), Mol. Reprod Dev., 29, 110-116), the use of inactivated virus, such as sendi virus (see, for example, Graham et al, (1969), Wistar Inst. Symp. Monogr., 9, 19), and the use of electrical stimulation (see, for example, Willasden, (1986), Nature, 320, 63-36 and Prather et al, (1987), Biol. Reprod., 37, 859-866). Use of electrical stimulation or cell fusion is preferred but by no means essential to this invention. By way of example, fusion of an enucleated oocyte with a donor cell may be accomplished by electro-pulsing in 0.3 M mannitol or 2.7 M sucrose solution. It has been surprisingly found by the inventors that activation by multiple electrical pulses spaced in their order of application gives rise to embryos capable of implantation and development to term unexpectedly superior to other methods. The same initial electrical pulse can be used to fuse the karyoplast and enucleated oocyte (simultaneous fusion and activation), or alternatively fusion and activation can be conducted sequentially when fusion occurs in Calcium-free medium. Activation by multiple electrical pulses results in multiple increases in intracellular calcium, mimicking the multiple transient increases that occur immediately following fertilisation. Multiple increases in intracellular calcium can also be achieved by other means, including by multiple treatments with chemical inducers such as the calcium ionophore ionomycin. These transient increases in intracellular calcium signal the resumption of meiosis. By way of example 2 to 6 electrical pulses may be delivered to the entities at an interval between each pulse of from one minute to sixty minutes, such as 2 pulses 30 minutes apart. Each pulse may be in the form of a set of pulses, such as 2 to 4 pulses, spread from each other by 1 to 20 seconds. DC pulses are generally used at a voltage such as 150v/mm for a duration such as 60p/s, and generally with a pre- and post-pulse alternating current.
WO 99/46982 PCT/AU99/00165 Direct micro injection of the karyoplast into an enucleated porcine oocyte may be carried out by conventional method, such as disclosed by Ritchie Campbell, J Reproduction and Fertility Abstract Series No. 15, page 60. As another example, a karyoplast may be introduced by injection into an enucleated porcine oocyte in a calcium free medium.
Enucleation of the porcine oocyte and transfer of the porcine donor karyoplast may be carried out as soon as the oocyte reaches the Metaphase II stage. This would generally coincide with the postonset of maturation in vitro, after collection of ovaries from slaughtered ovulating pigs, or following hormone treatment in vivo.
The donor karyoplast, whether transferred directly into the cell, or transferred via fusion of the donor cell with the enucleated porcine oocyte is synchronized at the GI or GO state. In this regard, the cell cycle has four distinct phases, G1, S, G2 and M, as is well known in the art. GO is a quiescent stage of low metabolic activity. The beginning event in the cell cycle is called start which takes place at the beginning of the G1 phase. Once a cell has passed through start, it passes through the remainder of the G1 phase, which is the pre-DNA synthesis stage. The second stage, the S phase, is the stage where DNA synthesis takes place. The G2 phase follows, which is the period between DNA synthesis and mitosis. Metaphase occurs during mitosis, which is referred to as the M phase.
Preferably, karyoplasts may be synchronized at the G1 state using a DNA synthesis inhibitor and/or use of a microtubule inhibitor which, on following removal of the inhibitor(s), results in synchronization of the karyoplast at the G1 state, or by means other than DNA inhibition, excluding serum starvation, for example cdk kinase inhibitors such as Butyrolactone I (Motlik et al (1998) Theriogeneology 49: 461-469). Examples of DNA synthesis inhibitors include: aphidicolin, hydroxyurea, cytosine arabinoside, 5-fluorouracil, n-ethylmalemide and etoposide.
Any microtubule inhibitor may be used in this invention including nocodazole, colchecine or colcemid. Alternatively, a microtubule stabilizer such as, for example, taxol may be used.
Karyoplasts may, for example, be synchronized at G1 by the use of a microtubule inhibitor such WO 99/46982 PCT/AU99/00165 -6as nocodazole (to give a population of nuclei at the metaphase) followed by treatment with a DNA synthesis inhibitor such as aphidicolin in which the nuclei progress to an arrest at the G1 state.
Alternatively only one of the aforementioned inhibitors may be utilised, or another means as discussed above which does not involve DNA synthesis inhibition. Karyoplasts may be synchronized in the GO state by nutrient deprivation, such as incubation in a low serum containing medium, as is known in the art, or by chemical treatment.
Donor karyoplasts (such as cells) may be incubated in a standard culture medium with a DNA synthesis inhibitor and/or microtubule inhibitor for a time sufficient to synchronize the cells at the G1 state. This can be readily observed by microscopic observations. DNA synthesis inhibitors and/or microtubule inhibitors may be used, for example, in an amount of from about 0.01 gg/ml to about 50 g/ml, such as about 1-5 /g/ml culture medium. Microtubule inhibitors fix the cells at the M phase. After removal of microtubule inhibitor from the cell media, which can conveniently be done by washing the cells, cells pass to the G1 phase after about 30 minutes to 6 hours in a uniform manner such that a plurality of cells in the G1 phase can be conveniently prepared. A DNA synthesis inhibitor synchronises cells at the G1 phase. Removal of a DNA synthesis inhibitor from cell media allows the cell cycle to proceed. Similarly donor karyoplasts may be synchronized in the GO state as described above.
Donor cells may be any porcine somatic cell, for example a foetal embryonic fibroblast cell, mammary cell, smooth muscle cell etc. Any somatic cell may be utilised. Porcine embryonic foetal fibroblast cells are particularly preferred. The donor cell may, by way of further example, be a porcine embryonic cell, such as a totipotent blastomere, for example a 16-32 cell mass (morula), or a cell derived from a porcine blastocyst, such as a totipotent cell from the inner cell mass of the blastocyst. The donor cell may be subject to conventional recombinant DNA manipulation where the DNA within the cell has been subject to recombinant DNA technology.
For example, genes may be deleted, duplicated, activated or modified by gene additions, gene targeting, gene knock-outs, transgenesis with exogenous constructs which may or may not contain selectable markers may be accomplished by techniques such as microinjection, electroporation, WO 99/46982 PCT/AU99/00165 -7viral-mediated transfection, lipofectin, calcium-phosphate precipitation (Lovell-Badge, "Introduction of DNA into embryonic stem cells" in: Teratocarcinomers and Embryonic Stem Cells: A Practical Approach, IRL Press, Oxford, E.J. Robertson, ed. pp 153-182, 1987; Molecular Cloning: A Laboratory Manual, Volume 2 3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, Sambrook, Fritsch and Maniatis Ed. pp 15.3-15.50, 16.3-16.68, 1989).
The resulting nuclear transferred cell following transfer of the nucleus of the porcine donor karyoplast into an enucleated porcine oocyte may be incubated in culture medium to allow one or more cell divisions to give a plurality of porcine embryonic cells. Porcine embryonic cells as referred to herein have the capacity, on implantation into a pregnancy competent porcine uterus, to develop into a porcine foetus. Porcine embryonic cells may contain, for example, 1, 2, 4, 8, 16 or 32 cells, or more. Cell division is a relatively rapid event and can be monitored by microscopic analysis. The porcine embryonic cells may be used directly for the production of cloned pigs, or alternatively may be conveniently stored, such as by being frozen in liquid nitrogen for subsequent use.
The nuclear transferred cell may be incubated to form a 2 to 32 cell mass, such as a 2 to 16 cell mass, whereafter the cell mass is synchronized at the G1 or GO state as mentioned above. An nuclear transferred karyoplast may be isolated from the cell mass, and transferred into a second enucleated oocyte at the Metaphase II stage of development to give a second nuclear transferred cell, which may be cultured in vivo to allow one or more cell divisions to give porcine embryonic cells.
A single nuclear transferred porcine embryonic cell or plurality of cells produced according to this invention may be treated with an agent, such as cytochalasin B, so as to prevent cell division, but not nuclear division, whereafter multiple karyoplasts may be removed therefrom and used for subsequent nuclear transfer according to methods described herein (which may be regarded as serial nuclear transfer). Porcine embryonic cells as referred to herein include those treated with an agent such as cytochalasin B, or other agents.
WO 99/46982 PCT/AU99/00165 -8- In accordance with another aspect of this invention a nuclear transferred porcine embryonic cell or plurality of cells is treated with an agent which prevents cell division but not nuclear division, such that a karyoplast isolated therefrom is derived from a cell having multiple nuclei.
In another aspect of this invention there is provided a process for the clonal generation of pigs which process comprises providing a porcine oocyte at the Metaphase II stage of development from which the nucleus is removed, transferring a porcine donor karyoplast at the G1 state into the oocyte to give an NT cell, culturing the NT cell in vivo to allow successive cell division to give nuclear transferred porcine embryonic cells, and thereafter transferring a plurality of porcine embryonic cells so produced into a pregnancy competent uterus of a female pig which at conclusion of the pregnancy term gives rise to a plurality of genetically identical off-spring.
The clonal generation of pigs generally involves introducing into a pregnancy competent uterine environment of a female pig a plurality of embryonic cells as herein described. For example, from 5 to 50 embryonic cells may be introduced into the uterine environment according to standard procedures as used in the animal husbandry field or embryo development in gestational animals.
The blastocysts may be inserted into the uterus using an appropriate device, such as a catheter or alternatively may be introduced into a fallopian tube for passage into the uterus. Non surgical procedures may also be used. The recipient female animal may be primed with the embryonic cells at or about the time of ovulation which may occur naturally, or as a result of induction according to established procedures such as by administration of appropriate hormonal regimes known in the art.
According to a further aspect there are provided genetically identical pigs when prepared according to the above process.
In another aspect this invention relates to progeny of pigs produced according to this invention (which may be referred to as nuclear transfer pigs (or NT pigs)). Progeny result from crossing an NT pig with another pig to give offspring piglets, that is progeny. The other pig may be an NT pig WO 99/46982 PCT/AU99/00165 -9or any other pig (for example selected for a particular trait). A progeny animal contains a part of the genetic complement of the original porcine donor karyoplast, which can be conveniently detected, for example, by DNA markers.
According to another aspect of this invention there is provided a cloned pig produced from a nuclear transferred (NT) porcine embryonic cell. The present invention as described herein provides for implantation competent nuclear transferred cells that give rise to cloned pigs. In this regard the progeny or cloned pigs contain the identical DNA to that of the karyoplast used in their production as described herein. Accordingly animals of significant agricultural fitness may be produced expressing desired beneficial traits such as low fat meat, rapid growth, resistance to disease or suitability of organs for transplantation.
In a further aspect this invention relates to the use of cloned pigs as herein described in agriculture, for organ production, or oocyte and embryo production. The capacity to clonally manipulate pigs means that desirable characteristics can be directly exploited in the aforementioned areas. Thus, in agriculture, low fat meat can be produced by usage of a donor karyoplast expressing such a characteristic or induced to express such a characteristic by means of genetic manipulation, such as homologous recombination. By such an approach, the cloned pigs can be used in general for highly efficient and desirable agricultural pursuits, for organ production for use in human transplants (for example, where antigens have been removed, masked or attenuated by means such as genetic manipulation, for example homologous recombination), or for oocyte and embryo production.
The present invention will now be described with reference to the following non-limiting examples.
Example 1 Collection of Oocytes from sows Pregnant crossbred Large White X Landrace sows were aborted by intramuscular (IM) injection of 1 mg prostaglandin F2 analog (Cloprostenol; Estrumate, Pitman-Moore, NSW, Australia) WO 99/46982 PCT/AU99/00165 between twenty five and forty days after mating followed by a second injection of 0.5 mg Cloprostenol twenty four hours later. One thousand international units of eCG (Pregnecol, Heriot AgVet, Vic, Australia) was administered (IM) at the same time as the second injection of Cloprostenol. Ovulation was induced by an IM injection of 500 iu hCG (Chorulon, Intervet, NSW, Australia) administered approximately seventy two hours after hCG. Oocytes were collected by surgically flushing oviducts forty eight to fifty two hours after hCG injection.
Culture of ova In vitro culture of oocytes, embryos and nuclear transfer embryos was conducted in 25 pl droplets of Whitten's medium (Whitten WK, 1971, in G Raspe, ed Advances in the Biosciences, Pergamon Press: Oxford, pp 129-141) supplemented with 15 mg/ml bovine serum albumin (BSA) under paraffin oil in a plastic petrie dish under an atmosphere of 5% CO 2 5% 0 2 and 90% N 2 in humidified air at 38-6C.
Example 2 Enucleation of Oocytes Oocytes were enucleated by aspirating the first polar body and adjacent cytoplasm (approximately of cytoplasm) using a bevelled pipette (40 ptm in diameter) in PB1 10% Fetal Calf Serum containing 7.5 zg/ml Cytochalasin B 5/g/ml Hoechst 33342 (Sigma). Enucleation was confirmed by fluorescent staining of the aspirated portion of cytoplasm. Enucleated oocytes were cultured in Whitten's medium (WM) in a 5% CO 2 incubator until reconstruction of karyoplasts.
Reaggregation, fusion and activation of NT cells An individual karyoplast was inserted into the perivitelline space of each enucleated oocyte. The karyoplast-oocyte complexes were cultured in WM medium until activation and fusion. Fusion and activation of the karyoplast-oocyte complexes was induced using a BTX Electro Cell Manipulator ECM 2001. The complexes were first washed in fusion medium containing 0.3M Mannitol/100M CaCl 2 MM MgSO 4 /0.01% polyvinylalcohol and then placed between two wire electrodes (1 mm apart) of the fusion chamber (450-10WG, BTX, CA) with 0.1 ml of fusion medium. Activation WO 99/46982 PCT/AU99/00165 -11and membrane fusion may be induced by two sets of DC pulses (for example 150v/mm, spaced from 5 seconds to one hour apart, preferably 30 minutes apart, with a pre- and post-pulse alternating current (AC) field of 45v, IMHz for 5 seconds each. Each set of DC pulses may comprise 1 or 2 closely spaced pulses. Where DC pulses are employed (a couplet) the pulses may be spaced from 1 to 20 seconds. NT embryos were placed in culture medium with or without cytochalasin B (CB) 7.5,g/ml for 1-3 hours immediately following activation. Whilst not essential to the invention CB is used to prevent expulsion of chromosomes and aneuploidy following activation.
Results obtained are shown in the following tables: Table 1 Metaphase arrest induced in porcine blastomere nuclei following treatment with nocodazole (NZ) dose x duration Duration of exposure NZ concentration Blastomeres at M 4h 1 ptg/ml 14/58 (24%) 7h 1 pug/ml 54/133 (41%) h 1 Ig/ml 257/267 (96%) h 0.5 gg/ml 101/133 (76%) Control 15/291 Table 2 In vitro development of porcine morulae following NZ treatment Repeats Duration Dose Development to blastocyst 4 15 h 1 zg/ml 17/30(57%) 3 15 h 0.5 ig/ml 14/20 3 15h Control 15/20(75%) WO 99/46982 PCT/AU99/00165 -12- Nuclear transfer results using karyoplasts at three different stages of the cellcycle Table 3 Karyoplast Cytoplast No. n 2-cell 4-cell Morula Blastocysts Cell No. of stage stage reps. blastocysts S-phase S-phase 7x 159 85 a 3 5 b 6 b 6 a 32.5±4.0 (53) (22) (10) (4) Metaphase M II 3x 53 29 10 b 2 b Ob (19) (0) Gl M11 4x 42 3 0 b 20c 12 9C 26.3±3.4 (71) (48) (29) (21) Legend: Within each column, numbers with different superscripts are significantly different (P<0.05).
S phase was achieved by oocyte activation; Metaphase was achieved by treatment with nocodazole; S phase was achieved by treatment with nocodazole and aphidocolin (Verma et al (1999). Therio 51,215).
Example 3 Development of Nuclear Transfer Embryos Derived From Differentiated Cells at G1 Foetal fibroblasts were isolated from d 25 porcine embryos (although embryos of other ages are also usable).
About 60% of cells in isolated unsynchronized foetal fibroblast cell populations are at the G1 phase of the cell cycle.
Foetal fibroblasts synchronised at G1 were prepared by isoleucine deprivation in in vitro culture.
Cells were incubated in isoleucine-free RPM1 with 10% foetal bovine serum for 2 d.
Unsynchronized and synchronized cells were used as karyoplasts to prepare nuclear transfer embryos, and morula/blastocyst development was determined. Results are shown in Table.
WO 99/46982 PCT/AU99/00165 -13- Table 4 reps n fused 2 cell 4 cell Morula/ blastocyst Unsynchronised 4x 84 65 51 24 2(3) (79) G1 synchronised 4x 122 91 62 29 6(7) (68) (32) Legend: Numbers in brackets are percentage of oocytes fused.
Results show that porcine nuclear transfer embryos can be derived from differentiated karyoplast at G1.
Example 4 Embryo Transfer of Nuclear Transfer Embryo Pregnant crossbred Large White X Landrace sows are aborted by intramuscular (IM) injection of 1 mg prostaglandin F2 analog (Cloprostenol; Estrumate, Pitman-Moore, NSW, Australia) between twenty five and forty days after mating followed by a second injection of 0.5 mg Cloprostenol twenty four hours later. Five hundred international units of eCG (Pregnecol, Heriot AgVet, Vic, Australia) is administered (IM) at the same time as the second injection of Cloprostenol. Ovulation is induced by an IM injection of 500 iu hCG (Chorulon, Intervet, NSW, Australia) administered approximately seventy two hours after eCG. Twenty-five to thirty, 4-cell embryos surgically transferred to the oviduct of a sow seventy two hours after the hCG injection result in a litter of to 8 piglets following a successful pregnancy.
Example Production of NT Embryos Oocytes were collected from superovulated Large White x Landrace donor pigs 48-52 h post hCG, and denuded of cumulus by pipetting and hylauronidase treatment. Oocytes were enucleated by removal of the first polar body and adjacent cytoplasm, and activated and fused to foetal fibroblasts WO 99/46982 PCT/AU99/00165 -14simultaneously at 54-56 h post hCG using two sets of DC pulses (1.5 kV/cm, 60ps x 2) given minutes apart in 0.3M mannitol solution containing 0.1 mM CaCI 2 0.1 mM MgSO 4 and 0.01% PVA. NT embryos were placed in culture medium with or without cytochalasin B (CB) for 1-3 hours immediately following activation. CB is used to prevent expulsion of chromosomes and aneuploidy following activation. Fibroblasts were obtained from day 25 fetuses and cultured in DMEM plus 10% FBS. Cells at passage 3 to 5 were made quiescent (that is, in the GO phase) by culture for 5 days at 0.5% FBS. For example, early passage foetal fibroblasts were plated at a density of 5 x 104/cm 2 in DMEM 10% foetal bovine serum. After 48 hours the medium was changed to DMEM 0.5% foetal bovine serum. 5 days later the cells were harvested by tripsin digestion and resuspended in DMEM 10% foetal bovine serum. NT embryos were cultured in 25p1 droplets of NCSU23 (Petters and Wells (1993), JReprodFert Suppl 48, 61-73) with 0.4% bovine serum albumin (BSA) under paraffin oil in a plastic petri dish under an atmosphere of
CO
2 5% 02, 90% N 2 at 38.6 0 C. 10% foetal bovine serum was added.
The in vitro development of NT embryos using this procedure is shown in Table 4.
Table 5 Development of nuclear transfer embryos constructed with porcine fetal fibroblasts development to no. oocytes no. successfully 2 cell 4 cell morula blastocyst fused 127 103 58(56) 27(26) 7(7) 3(3) data is the sum of 5 replicates numbers in brackets are percentage of embryos which successfully fused.
Fusion and activation rates obtained using porcine fetal fibroblasts were similar to those reported for sheep and cattle previously (loc. cit.). However, development to the blastocyst stage was lower WO 99/46982 PCT/AU99/00165 suggesting that there is a difference between the pig and these species in the ease with which fetal fibroblast nuclei can be reprogrammed using current nuclear transfer methods.
Transfer of NT Embryos Embryos produced using the above method were transferred to recipient animals to allow them to develop to term. The protocol used is described below.
Because the recipient oocyte is damaged during the nuclear transfer process, the majority embryos were encapsulated in agar (or agarose) to maintain their integrity and prevent immunological attack.
Because in vitro culture conditions do not mimic those in vivo, NT embryos were transferred to the ligated oviduct of a mated recipient the day after reconstruction to maximize development.
Transferred embryos were collected 3 to 4 days later and morula and blastocyst embryos transferred to the uterus of a mated or unmated second recipient. The type of recipient used depended on the number of NT and in vivo derived embryos recovered from the first recipient.
When this number was low embryos were transferred to a mated recipient to maximize the potential for their development.
The number of NT embryos transferred, the type of second recipient used and pregnancy outcome is shown in Table WO 99/46982 PCT/AU99/00165 -16- Transfer of NT Embryos Table 6 Date No. NT embryos No.NT in vivo Transferred Pregnancy transferred to derived embryos to unmated status of temporary recovered/transferred or mated recipient recipient from temporary 2nd recipient recipient 2/10 16/10 23/10 30/10 8M+2BNT 10C 1M 1BNT +OC unmated mated unmated mated 4MNT 12C IBNT 1C 6/11 27/11 1/12 4/12 8/12 11/12 15/12 1M+2BNT 10C mated/one side flushed 9 piglets born returned 4 piglets born 6 piglets born pregnant pregnant returned pregnant returned returned pregnant 1M 1BNT +9NT 7C 4M 4NT 18C mated unmated 3MNT 8C 4MNT 3C mated/one side flushed mated/one side flushed 5MNT 1BNT 7C 3MNT 13C unmated unmated unmated 18/12 42 4NT +14C WO 99/46982 PCT/AU99/00165 -17- NT 4-8 cell NT embryos MNT NT embryos at morula stage BNT NT embryos at blastocyst stage C carrier embryos not derived by NT pregnancy determined using real time ultrasound under analysis Pregnancy may be terminated at any stage to provide easy analysis of the genotype of implanted embryos. Identification of implanted embryos with the genotype of karyoplasts used in nuclear transfer verified implantation capacity of nuclear transfer embryos.
Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising" or the term "includes" or variations thereof, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. In this regard, in construing the claim scope, an embodiment where one or more features is added to any of claims is to be regarded as within the scope of the invention given that the essential features of the invention as claimed are included in such an embodiment.
Claims (19)
1. A process for the production of nuclear transferred porcine embryonic cells which includes providing a porcine oocyte at the Metaphase II stage of development from which the nucleus is removed, transferring a porcine karyoplast at the G1 state into the oocyte to give a nuclear transferred porcine embryonic cell and optionally culturing the nuclear transferred cell in vitro to allow one or more cell divisions to give a plurality of nuclear transferred porcine embryonic cells, wherein said karyoplast is synchronized at the G1 state by use of DNA synthesis inhibitor and/or microtubule inhibitor and/or use of means 10 which do not involve serum starvation of cells.
2. A process according to claim 1 wherein the nuclear transferred porcine embryonic cell or plurality of cells, such as a 2 to 32 cell mass, is synchronized at the G1 state, isolating a nuclear transferred karyoplast therefrom, and transferring said karyoplast into a second enucleated oocyte at the Metaphase II stage of development or to an enucleated zygote, or later stage embryo or embryonic cell to give a second nuclear transferred cell, which may be cultured in vitro to allow one or more cell divisions to give a plurality of nuclear transferred porcine embryonic cells. 20
3. A process according to claim 2 wherein the nuclear transferred porcine embryonic cell or plurality of cells is treated with an agent which prevents cell division but not nuclear division, such that a karyoplast isolated therefrom is derived from a cell possessing multiple nuclei.
4. A process for the production of porcine embryonic cells wherein the method of claim 3 is repeated a plurality of times.
A process for the clonal generation or propagation of pigs which process includes providing a porcine oocyte at the Metaphase II stage of development from which the P:\WPDOCSGRS\SPECI7109953.doc-24 Octbe., 2002 19 nucleus is removed, transferring a porcine donor karyoplast at the G1 state into the oocyte to give a nuclear transferred porcine embryonic cell, and thereafter culturing the nuclear transferred cell in vitro to allow one or more cell divisions to give a plurality of nuclear transferred porcine embryonic cells, and thereafter transferring a plurality of porcine embryonic cells so produced into a pregnancy competent uterus of a female pig which at conclusion of the pregnancy term gives rise to one or more genetically identical off-spring.
6. A process according to any of claims 1 to 5 in which the karyoplast is genetically altered or modified.
7. A process according to claim 1 wherein karyoplasts are synchronised at the G1 state by treatment with a microtubule inhibitor followed by treatment with a DNA synthesis inhibitor.
8. A process according to any of claims 1-7 wherein the DNA synthesis inhibitor is selected from one or more of aphidicolin, hydroxyurea, cytosine arabinoside, 5-fluorouracil, n- ethylmalemide and etoposide.
9. A process according to any of claims 1-8 wherein the microtubule inhibitor is selected from nocadazole, colchecine and colcemid.
A process according to claim 7 wherein said means are selected from use of a cdk kinase inhibitor and isoleucine deprivation.
11. A process according to any one of claims 1-6 wherein karyoplasts are synchronised at the G1 state by means which do not involve serum starvation of cells.
12. A process according to any of claims 1 to 11 wherein the porcine karyoplast at the G1 state is fused and activated in an enucleated porcine oocyte at the Metaphase II stage of P:\WPDOCS\GRS\SPECI\7109953.doc-24 Octob r 2002 development by application of multiple electrical pulses spaced in their order of application, or by other means of generating multiple transient increases in intracellular Ca levels.
13. A process according to claim 12 wherein from 1 to 6 pulses are delivered at an interval between each pulse of from one minute to sixty minutes.
14. A process according to claim 13 wherein pulses are applied at a thirty minute interval. 10
15. A process according to claim 12 wherein each pulse is a set of pulses of 2 to 4 pulses, spaced from each other by 1 to 20 seconds.
16. Porcine embryonic cells or cloned pigs when produced according to a process comprising or including a process as defined in any preceding claim.
17. A porcine embryo comprising nuclear transferred embryonic cells produced according to any of claims 1-4 and 6-15.
18. Progeny ofa pig according to claim 16. .i
19. A process according to any one of claims 1 to 15 which is a process for the production of porcine nuclear transferred embryos. DATED this 24th day of October, 2002 Relag Pty Ltd AND Garelag Pty Ltd By Its Patent Attorneys DAVIES COLLISON CAVE
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU29135/99A AU755743B2 (en) | 1998-03-16 | 1999-03-16 | Porcine nuclear transfer |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP2364A AUPP236498A0 (en) | 1998-03-16 | 1998-03-16 | Porcine nuclear transfer |
| AUPP2364 | 1998-03-16 | ||
| AUPP7720A AUPP772098A0 (en) | 1998-12-15 | 1998-12-15 | Porcine nuclear transfer |
| AUPP7720 | 1998-12-15 | ||
| PCT/AU1999/000165 WO1999046982A1 (en) | 1998-03-16 | 1999-03-16 | Porcine nuclear transfer |
| AU29135/99A AU755743B2 (en) | 1998-03-16 | 1999-03-16 | Porcine nuclear transfer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2913599A AU2913599A (en) | 1999-10-11 |
| AU755743B2 true AU755743B2 (en) | 2002-12-19 |
Family
ID=27153224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU29135/99A Ceased AU755743B2 (en) | 1998-03-16 | 1999-03-16 | Porcine nuclear transfer |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU755743B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU780366B2 (en) | 2000-01-20 | 2005-03-17 | Diatranz Otsuka Limited | Preparation and xenotransplantation of porcine islets |
-
1999
- 1999-03-16 AU AU29135/99A patent/AU755743B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2913599A (en) | 1999-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4081613B2 (en) | Stationary cell population for nuclear transfer | |
| AU742840B2 (en) | Cloning pigs using donor nuclei from differentiated cells | |
| JP2006340710A (en) | Inactive oocytes as recipient cytoplasm for nuclear transfer | |
| JP2002534118A (en) | Double nuclear transfer method and its result | |
| US20070107074A1 (en) | Porcine Nuclear Transfer | |
| EP1096850A1 (en) | A process of cell reprogramming through production of a heterokaryon | |
| AU7372500A (en) | Cloning pigs using donor cells or nuclei from differentiated cells and production of pluripotent porcine. | |
| NZ337792A (en) | Nuclear transfer and use in cloning | |
| Eyestone et al. | Nuclear transfer from somatic cells: applications in farm animal species | |
| AU755743B2 (en) | Porcine nuclear transfer | |
| US7291764B1 (en) | Cloning pigs using non-quiescent differentiated donor cells or nuclei | |
| US20050149999A1 (en) | Methods for cloning mammals using remodeling factors | |
| Escrıbá et al. | Reconstruction of the heteroparental diploid condition in rabbit zygotes by nuclear transfer | |
| US20040077077A1 (en) | Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same | |
| AU4277400A (en) | A process of cell reprogramming through production of a heterokaryon | |
| JP2005525098A (en) | Rabbit nuclear cloning method and its usage | |
| WO2001030970A2 (en) | Improved protocol for activation of oocytes | |
| AU2005225075A1 (en) | Cloning pigs using donor cells or nuclei from differentiated cells and production of pluripotent porcine | |
| MXPA00000202A (en) | Cloning pigs using donor nuclei from differentiated cells | |
| MXPA00000201A (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
| HK1090089B (en) | Quiescent cell populations for nuclear transfer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |